医学部 循環器内科学

原田 将英

ハラダ マサヒデ  (harada masahide)

基本情報

所属
藤田医科大学 医学部 医学科 循環器内科学 准教授

J-GLOBAL ID
200901026008784300
researchmap会員ID
6000014004

専門:臨床不整脈・心臓電気生理学 基礎電気生理学 カテーテルアブレーション ペースメーカー/ICD/CRTD

日本内科学会 総合内科専門医
日本循環器学会 専門医
日本不整脈心電学会 専門医(評議員)
日本心血管インターベンション治療学会 認定医
欧州心臓病学会 特別正会員(FESC)

学歴

 2

論文

 98
  • Yukitoshi Ikeya, Yasuo Okumura, Rikitake Kogawa, Koichi Nagashima, Toshiko Nakai, Katsuaki Yokoyama, Kazuki Iso, Takeshi Kato, Toyonobu Tsuda, Eizo Tachibana, Satoshi Hayashida, Hidehira Fukaya, Naruya Ishizue, Hidemori Hayashi, Shunsuke Kuroda, Kazumasa Sonoda, Shiro Nakahara, Yuichi Hori, Masahide Harada, Masato Murakami, Yu-Ki Iwasaki, Yoshiyasu Aizawa, Wataru Shimizu, Seiji Fukamizu, Mitsuru Takami, Kengo Kusano, Kohei Ishibashi, Tomoo Harada, Ikutaro Nakajima, Haruna Tabuchi, Mitsuhiro Kunimoto, Morio Shoda, Satoshi Higuchi, Itsuro Morishima, Yasunori Kanzaki, Ritsushi Kato, Yoshifumi Ikeda, Hisaki Makimoto, Tomoyuki Kabutoya, Kazuomi Kario, Takanori Arimoto, Yuichi Ninomiya, Issei Yoshimoto, Shingo Sasaki, Yusuke Kondo, Toshinori Chiba, Kennosuke Yamashita, Yosuke Mizuno, Masaru Inoue, Takeshi Ueyama, Jyunjiro Koyama, Takuo Tsurugi, Yoshiya Orita, Taku Asano, Toshiro Shinke, Kaoru Tanno, Kenta Murotani
    Journal of arrhythmia 40(3) 423-433 2024年6月  
    BACKGROUND: Despite the positive impact of implantable cardioverter defibrillators (ICDs) and wearable cardioverter defibrillators (WCDs) on prognosis, their implantation is often withheld especially in Japanese heart failure patients with reduced left ventricular ejection fraction (HFrEF) who have not experienced ventricular tachycardia (VT) or ventricular fibrillation (VF) for uncertain reasons. Recent advancements in heart failure (HF) medications have significantly improved the prognosis for HFrEF. Given this context, a critical reassessment of the treatment and prognosis of ICDs and WCDs is essential, as it has the potential to reshape awareness and treatment strategies for these patients. METHODS: We are initiating a prospective multicenter observational study for HFrEF patients eligible for ICD in primary and secondary prevention, and WCD, regardless of device use, including all consenting patients. Study subjects are to be enrolled from 31 participant hospitals located throughout Japan from April 1, 2023, to December 31, 2024, and each will be followed up for 1 year or more. The planned sample size is 651 cases. The primary endpoint is the rate of cardiac implantable electronic device implementation. Other endpoints include the incidence of VT/VF and sudden death, all-cause mortality, and HF hospitalization, other events. We will collect clinical background information plus each patient's symptoms, Clinical Frailty Scale score, laboratory test results, echocardiographic and electrocardiographic parameters, and serial changes will also be secondary endpoints. RESULTS: Not applicable. CONCLUSION: This study offers invaluable insights into understanding the role of ICD/WCD in Japanese HF patients in the new era of HF medication.
  • 坂口 英林, 成瀬 寛之, 石井 潤一, 山田 晶, 河合 秀樹, 村松 崇, 原田 将英, 西村 豪人, 皿井 正義, 簗瀬 正伸, 井澤 英夫
    日本循環器学会学術集会抄録集 88回 PJ043-1 2024年3月  
  • Taro Makino, Tomohide Ichikawa, Mari Amino, Mari Nakamura, Masayuki Koshikawa, Yuji Motoike, Yoshihiro Nomura, Masahide Harada, Yoshihiro Sobue, Eiichi Watanabe, Ken Kiyono, Koichiro Yoshioka, Yuji Ikari, Yukio Ozaki, Hideo Izawa
    Annals of Noninvasive Electrocardiology 28(6) 2023年11月  
    Background: We aimed to investigate the association between ventricular repolarization instability and sustained ventricular tachycardia and ventricular fibrillation (VT/VF) occurring within 48 h (acute-phase VT/VF) after the onset of acute coronary syndrome (ACS) and the prognostic role of repolarization instability and heart rate variability (HRV) after discharge from the hospital. Methods: We studied 572 ACS patients with a left ventricular ejection fraction >35%. The ventricular repolarization instability was assessed by the beat-to-beat T-wave amplitude variability (TAV) using high-resolution 24-h Holter ECGs recorded at a median of 11 days from the date of admission. We calculated the HRV parameters including the deceleration capacity (DC) and non-Gaussian index calculated on a 25 s timescale (λ25s). The DC and λ25s were dichotomized based on previous studies' thresholds. Results: Acute-phase VT/VF developed in 43 (7.5%) patients. In-hospital mortality was significantly higher among VT/VF patients (4.7% vs. 0.9%, p =.03). An adjusted logistic model showed that the maximum TAV (odds ratio 1.02, 95% confidence interval [CI] 1.00–1.29, p =.04) was associated with acute-phase VT/VF. During a median follow-up period of 2.1 years, 19 (3.3%) patients had cardiac deaths or resuscitated cardiac arrest. Acute-phase VT/VF (p =.12) and TAV (p =.72) were not significant predictors of survival. An age and sex-adjusted Cox model showed that the DC (p <.01), λ25s (p <.01), and emergency coronary intervention (p <.01) were independent predictors. Conclusion: T-wave amplitude variability was associated with acute-phase VT/VF, but the TAV was not predictive of survival post-discharge. The DC, λ25s, and emergency coronary intervention were independent predictors of survival.
  • Harada M, Okuzaki D, Yamauchi A, Ishikawa S, Nomura Y, Nishimura A, Motoike Y, Koshikawa M, Hitachi K, Tsuchida K, Amano K, Maekawa A, Takagi Y, Watanabe E, Ozaki Y, Izawa H
    PLoS One 18(4) e0283942 2023年4月4日  査読有り筆頭著者責任著者
    BACKGROUND: Circulating microRNAs (miRNAs, miR) have been considered as biomarkers reflecting the underlying pathophysiology in atrial fibrillation (AF). Nevertheless, miRNA expression in the peripheral blood samples might not reflect a cardiac phenomenon since most miRNAs are expressed in numerous organs. This study aimed to identify the cardiac-specific circulating miRNAs as biomarkers for AF. METHODS: Plasma samples were obtained from a luminal coronary sinus catheter (CS, cardiac-specific samples) and femoral venous sheath (FV, peripheral samples) in patients with AF and paroxysmal supraventricular tachycardia (control, CTL) undergoing catheter ablation. The circulating miRNA profiles were analyzed by small RNA sequencing. Differently expressed miRNAs between AF and CTL were identified in each sample of the CS and FV; miRNAs exhibiting similar expression patterns in the CS and FV samples were selected as candidates for cardiac-specific biomarkers. The selected miRNAs were related to the outcome of catheter ablation of AF. RESULTS: Small RNA sequencing detected 849 miRNAs. Among the top 30 most differently expressed miRNAs between AF and CTL, circulating hsa-miR-20b-5p, hsa-miR-330-3p, and hsa-miR-204-5p had a similar pattern in the CS and FV samples. Another set of peripheral blood samples was obtained from AF patients undergoing catheter ablation (n = 141). The expression of the miR-20b-5p and miR-330-3p, but not the miR-204-5p, negatively correlated with the echocardiographic left-atrial dimension and was decreased in patients with AF recurrence as compared to those without AF recurrence during a 1-year follow-up. CONCLUSION: Circulating miR-20b-5p and miR-330-3p can be cardiac-specific biomarkers for atrial remodeling progression and arrhythmia recurrence after catheter ablation in AF patients.
  • 坂口 英林, 成瀬 寛之, 石井 潤一, 山田 晶, 河合 秀樹, 村松 崇, 原田 将英, 皿井 正義, 簗瀬 正伸, 井澤 英夫
    日本循環器学会学術集会抄録集 87回 OJ34-9 2023年3月  

MISC

 66

書籍等出版物

 21

講演・口頭発表等

 6

共同研究・競争的資金等の研究課題

 8